[Skip to Content]
[Skip to Content Landing]
September 1978

Treatment of Adult Acute Nonlymphocytic Leukemia—1978

Author Affiliations

University of Minnesota Box 277, Mayo Memorial Building 420 Delaware St SE Minneapolis, MN 55455

Arch Intern Med. 1978;138(9):1333-1334. doi:10.1001/archinte.1978.03630340007004

Important advances in the treatment of adult acute nonlymphocytic leukemia (ANLL) have occurred in the last ten years. The percentage of patients achieving complete remission has increased strikingly, the median duration of these remissions has lengthened, and the percentage of long-term survivors has risen. Ten years ago, a 25% remission rate for adults with ANLL was exceptional. Five years ago, complete remission rates of 35% to 45% were routine. (See the article in this issue by Coltman et al reporting results from a Southwest Oncology Group (SWOG) study that enrolled patients in 1971 and 1972 [p 1342].) Today, complete remission rates of greater than 60% are regularly achieved using combinations that generally include an anthracycline antibiotic (daunorubicin hydrochloride or doxorubicin hydrochloride) and cytarabine.1,2 A complete remission rate of 82% of all patients treated, not simply those receiving adequate trials, has been reported using a combination of daunorubicin, cytarabine, and

First Page Preview View Large
First page PDF preview
First page PDF preview